معرفی
Marcel Nijland is a researcher at the University of Groningen, focusing on hematologic malignancies, particularly diffuse large B-cell lymphoma (DLBCL). His work integrates clinical outcomes, genetic profiling, and molecular biology to improve treatment strategies and prognostic understanding. He has co-supervised a PhD student in molecular imaging for lymphoproliferative disorders.
Research interests center on B-cell lymphomas, immunotherapy, and precision medicine. Key areas include:
- Prognostic factors in DLBCL (e.g., MYC rearrangements, tumor microenvironment)
- PET scan monitoring and genetic subtyping for outcome prediction
- Novel therapies like atezolizumab consolidation in high-risk cases
His recent articles highlight advancements in:
- Combining genomic data with imaging to tailor treatments
- Cell-free DNA analysis for Hodgkin lymphoma prognosis
- Immune-rich tumor microenvironment’s role in bone DLBCL survival
No scientific awards are explicitly listed, but his work has been featured in Nature Communications and Blood Advances. Collaborations span institutions across Europe, emphasizing translational research in lymphoma.
